Cytochrome C lyophilisate for solution preparation 10 mg

Cytochrome C lyophilisate for solution preparation 10 mg

SKU:2281
To favorites
Cytochrome lyophilisate for solution preparation metabolic agent, has an antihypoxic, trophic effect, stimulates regeneration processes, is a catalyst for cellular respiration
Active substance:Cytochrome C
Pharmacological group:Cardiac medications
Formulation:SOLUTION
Dosage mg:10
In stock
$80
11
Description
Features
Reviews

Instructions for Cytochrome C lyophilisate for solution preparation 10 mg

English product name
Cytocrom C

Release Form
eye drops 0.25%: fl. 2 ml with a drip lid.

Description Cytochrome C

Eye drops 0.25% 1 ml
cytochrome C 2.5 mg
2 ml - bottles with a drip lid (1) - packs of cardboard.

ATC codes
S01XA Other preparations for the treatment of diseases of the eye

Clinical-pharmacological groups / Group affiliation
Preparation stimulating regeneration processes for local use in ophthalmology

Active substance
cytochrome C

Pharmaco-therapeutic group Cytochrome C

Tissue regeneration stimulator

Storage Conditions
Store in a dry, light-proof place at a temperature of 4°C to 20°C.

Best before date
The shelf life is 2 years.
Keep the opened bottle in the refrigerator for no more than 3 days in a closed form.

Pharmacological effect Cytochrome C

Metabolic preparation, has antihypoxic, trophic effect, stimulates regeneration processes. It is a catalyst for cellular respiration.

The mechanism of action of the drug is connected with the presence of iron in the prostetic group, which is able to pass from the oxidized state to the reduced state. As a result, endogenous redox reactions and metabolic processes in tissues are accelerated, oxygen utilization is improved and tissue hypoxia is reduced in various pathological conditions.

Testimony Cytochrome C

  • Corneal dystrophy (primary and secondary)
  • clouding of the cornea;
  • Cytochrome C is used in combination therapy as a tissue respiration enhancing agent in conditions accompanied by a disorder of
  • oxidizing-reducing processes in the body: 
  • infant asphyxia; severe injuries;
  • before and after operative intervention (with the aim of preventing shock), 
  • during remission of bronchial asthma with the presence of respiratory insufficiency, in patients with chronic obstructive
  • pulmonary disease and heart failure; 
  • in case of viral hepatitis, complicated by a hepatic coma; 
  • in case of poisoning with sleeping preparations and carbon monoxide.
  • keratitis (in epithelization).

Method of use, course and dosage

Locally, burying in a conjunctival bag for 1-2 drops three - four times a day.

Overdose
No data available.

Drug interaction
Not described.

  • Nosology (ICD codes)
  • H16
  • Keratitis
  • H17
  • Scarring and clouding of the cornea
  • H18.4
  • Corneal degeneration
Features
Active substance
Pharmacological group
Formulation
Dosage mg
Pills in 1 package
Country of origin
Brand
Expiration Date
No reviews yet — your comment may be first.
All reviews 0
general rating